No serious adverse events were seen in the study patients. The investigators suggested rosiglitazone may serve as a "good alternative to current systemic immunosuppressants used for severe AD," but urged caution in interpreting the promising results because of study design limitations and two previous randomized trials of rosiglitazone in psoriasis that failed to demonstrate any notable efficacy, compared with placebo.
The study was supported in part by the National Institute of Arthritis and Case Medical Center.
No financial disclosures were reported by the authors.